| Literature DB >> 22522993 |
Mislav Cerovec1, Branimir Anić, Ivan Padjen, Nada Cikes.
Abstract
AIM: To identify systemic lupus erythematosus (SLE) patients diagnosed and treated at the outpatient clinic of our Division fulfilling at least four American College of Rheumatology (ACR) classification criteria at the time of the study, to determine the prevalence of each of the criteria at three different time points, and to compare the data with similar studies.Entities:
Mesh:
Year: 2012 PMID: 22522993 PMCID: PMC3342646 DOI: 10.3325/cmj.2012.53.149
Source DB: PubMed Journal: Croat Med J ISSN: 0353-9504 Impact factor: 1.351
The prevalence of the American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in 162 patients fulfilling at least 4 criteria at the time when the study was conducted (data available for 162 patients), at the time of establishing the diagnosis, and at disease onset (data available for 125/162 and 78/162 patients, respectively)
| No (%) of patients fulfilling each criterion at: | ||||
|---|---|---|---|---|
| ACR classification criteria for SLE | SLE onset | SLE diagnosis | time when the study was conducted | |
| 1 | Malar rash | 21 (26.9) | 48 (38.4) | 100 (61.7) |
| 2 | Discoid rash | 4 (5.1) | 7 (5.6) | 24 (14.8) |
| 3 | Photosensitivity | 18 (23.1) | 43 (34.4) | 84 (51.9) |
| 4 | Oral ulcers | 11 (14.1) | 18 (14.4) | 27 (16.7) |
| 5 | Arthritis | 41 (52.6) | 69 (55.2) | 115 (71.0) |
| 6 | Serositis | 10 (12.8) | 19 (15.2) | 28 (17.3) |
| a | Pleuritis | 6 (7.7) | 13 (10.4) | 17 (10.5) |
| b | Pericarditis | 2 (2.6) | 9 (7.2) | 11 (6.8) |
| c | Sub-criterion not determined | 2 (2.6) | 3 (2.4) | 5 (3.1) |
| 7 | Renal disorder | 6 (7.7) | 19 (15.2) | 42 (25.9) |
| 8 | Neurologic disorder | 2 (2.6) | 3 (2.4) | 9 (5.6) |
| a | Seizures | 2 (2.6) | 3 (2.4) | 6 (3.7) |
| b | Psychosis | 0 (0.0) | 0 (0.0) | 3 (1.9) |
| 9 | Hematologic disorder | 29 (37.2) | 67 (53.6) | 114 (70.4) |
| a | Hemolytic anemia | 3 (3.8) | 11 (8.8) | 14 (8.6) |
| b | Leukopenia | 18 (23.1) | 43 (34.4) | 75 (46.3) |
| c | Lymphopenia | 5 (6.4) | 26 (20.8) | 53 (32.7) |
| d | Thrombocytopenia | 13 (16.7) | 19 (15.2) | 26 (16.0) |
| e | Sub-criterion not determined | 0 (0.0) | 1 (0.8) | 5 (3.1) |
| 10 | Immunologic disorder | 12 (15.4) | 74 (59.2) | 145 (89.5) |
| a | Anti-DNA | 10 (12.8) | 68 (54.4) | 136 (84.0) |
| b | Anti-Sm | NA* | NA* | NA* |
| c | Antiphospholipid antibodies | 3 (3.8) | 32 (25.6) | 45 (27.8) |
| d | Sub-criterion not determined | 1 (1.3) | 3 (2.4) | 8 (4.9) |
| 11 | Antinuclear antibody | 18 (23.1) | 110 (88.0) | 155 (95.7) |
*NA – data not available.
Comparison of the prevalence of each of the American College of Rheumatology (ACR) classification criteria between our study (Croatia) and similar studies conducted in patients diagnosed with systemic lupus erythematosus (SLE)
| The percentage of patients with the criterion | USA ( | Europe ( | Germany ( | Norway ( | Croatia |
|---|---|---|---|---|---|
| Malar rash | 57.0 | 26.4 | 67.0 | 51.0 | 61.7 |
| Discoid rash | 18.0 | 5.4 | 44.0 | 16.0 | 14.8 |
| Photosensitivity | 43.0 | 18.7 | 72.0 | 49.0 | 51.9 |
| Oral ulcers | 27.0 | 8.9 | 33.0 | 2.0 | 16.7 |
| Arthritis | 86.0 | 41.3 | 71.0 | 87.0 | 71.0 |
| Serositis | 56.0 | 12.9 | 30.0 | 42.0 | 17.3 |
| Renal disorder | 51.0 | 22.2 | 42.0 | 22.0 | 25.9 |
| Neurologic disorder | 20.0 | 13.6 | 21.0 | 11.0 | 5.6 |
| Hematologic disorder | 59.0 | 12.8 | 97.0 | 46.0 | 70.4 |
| Immunologic disorder | 85.0 | NA* | 96.0 | 67.0 | 89.5 |
| Antinuclear antibody | 99.0 | 90.5 | 96.0 | 100.0 | 95.7 |
| Number of patients | 177 | 1000 | 338 | 55 | 162 |
*NA – data not available.